Aetna to remain in all current exchanges in 2017, teases expansion

Aetna won’t join insurers like UnitedHealth and Humana in leaving the Affordable Care Act’s health insurance marketplaces—and may expand into new states, according to the Wall Street Journal.

The company currently offers plans on 15 ACA state exchanges, and Aetna spokesman T.J. Crawford told the WSJ it has submitted rate proposals for 2017 with “no plans at this point to withdraw from any of those states.”

Crawford went on to say Aetna’s filings with regulators “preserved our options to enter certain new geographies pending careful evaluation of marketplace conditions.” While the WSJ quoted an Oklahoma regulator who claims he had been informed Aetna would begin selling exchange plans there in 2017, Crawford said the company hasn’t made any final decisions on expansion and won’t do so until September.

The announcement followed positive statements about the marketplaces by Aetna CEO Mark Bertolini, who in April called the exchanges a “good investment” based on how much it would’ve cost the company to find the same number of new customers without the Affordable Care Act. In its first quarter earnings report, Aetna said its signed up more than 900,000 people for individual coverage through the marketplaces.

Aetna’s exchange expansion plans remain separate from Humana while their merger awaits approval from regulators, as Aetna will still offer plans in Virginia, one of the four states Humana is exiting in 2017. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup